A phase II study of the combination of docetaxel and bevacizumab for previously treated non-small cell lung cancer

OBJECTIVE: The standard therapies for previously treated advanced non-small cell lung cancer (NSCLC) include docetaxel (DOC). Bevacizumab (BV), an antivascular endothelial growth factor (VEGF) antibody, increases the antitumor effect of cytotoxic anticancer agents. A BV-containing combination regime...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Tetsuo, Nakagawa, Yoshiko, Asai, Yasuo, Tsujino, Ichirou, Takahashi, Noriaki, Gon, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Clinical Research Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683925/
https://www.ncbi.nlm.nih.gov/pubmed/31179803
http://dx.doi.org/10.1177/0300060519852202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683925/
https://www.ncbi.nlm.nih.gov/pubmed/31179803
http://dx.doi.org/10.1177/0300060519852202

Ejemplares similares